A study led by researchers from The University of Texas MD Anderson Cancer Center found a significant association between cholesterol-lowering drugs commonly known as statins and survival rates of triple-negative breast cancer patients. Since statins are low in cost, easy to access and produce minimal side effects, this could have an important impact on outcomes for this aggressive disease.
A new DNA sequencing approach developed by MD Anderson researchers overcomes technical challenges with earlier techniques to give deeper insights into breast cancer evolution.
Breast cancer stem cells from patients with different racial and ethnic backgrounds showed important differences in activation of immune response-related genes in mouse models of triple-negative breast cancer.
Genetic modifier HDAC6 was found to control tumor growth and halt metastasis in triple-negative breast cancer in vivo, according to a new study published in the journal Cancer Research by investigators at the GW Cancer Center.